ULTRACEF Drug Patent Profile
✉ Email this page to a colleague
When do Ultracef patents expire, and when can generic versions of Ultracef launch?
Ultracef is a drug marketed by Bristol and Apothecon and is included in four NDAs.
The generic ingredient in ULTRACEF is cefadroxil/cefadroxil hemihydrate. Twenty-two suppliers are listed for this compound. Additional details are available on the cefadroxil/cefadroxil hemihydrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ULTRACEF?
- What are the global sales for ULTRACEF?
- What is Average Wholesale Price for ULTRACEF?
Summary for ULTRACEF
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 51 |
| Patent Applications: | 6,651 |
| DailyMed Link: | ULTRACEF at DailyMed |
US Patents and Regulatory Information for ULTRACEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | ULTRACEF | cefadroxil/cefadroxil hemihydrate | CAPSULE;ORAL | 062378-001 | Mar 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol | ULTRACEF | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 062376-003 | Mar 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol | ULTRACEF | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 062376-001 | Mar 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol | ULTRACEF | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 062376-002 | Mar 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
